Ellipses Pharma
Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow. The company aims to develop new treatments for cancer that address unmet clinical needs, utilizing a unique approach that involves expert clinical trials, scientific validation, and rapid scalability. Ellipses is committed to making a difference in cancer treatment development by leveraging a large network of oncology key opinion leaders, innovative trial designs, and a disruptive funding model to bring promising cancer medicines to patients faster.
Industries
Nr. of Employees
small (1-50)
Ellipses Pharma
10 Stratton Street, W1J 8LG London
Patents
Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine
US-12624027-B2
View DetailsMethods of treating cancer using compounds containing a vascular disrupting agent
US-9937267-B2
View Details
Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine
US-12624027-B2
View DetailsMethods of treating cancer using compounds containing a vascular disrupting agent
US-9937267-B2
View DetailsProducts
Molecularly targeted oncology assets (clinical-stage)
Clinical development programs for next‑generation targeted small molecules directed at molecular alterations (e.g., RET alterations, FLT3/Aurora kinase inhibition) with early‑phase clinical data and regulatory milestones.
Diverse oncology modality portfolio (preclinical to clinical)
A portfolio approach developing a range of modalities including immuno‑oncology agents, peptide‑drug conjugates, nanoparticle chemotherapies and selective receptor modulators across preclinical and clinical stages.
Molecularly targeted oncology assets (clinical-stage)
Clinical development programs for next‑generation targeted small molecules directed at molecular alterations (e.g., RET alterations, FLT3/Aurora kinase inhibition) with early‑phase clinical data and regulatory milestones.
Diverse oncology modality portfolio (preclinical to clinical)
A portfolio approach developing a range of modalities including immuno‑oncology agents, peptide‑drug conjugates, nanoparticle chemotherapies and selective receptor modulators across preclinical and clinical stages.
Services
End‑to‑end development services spanning candidate validation, clinical trial design and execution, regulatory strategy, and data dissemination for oncology assets.
Independent expert appraisal of assets and indications via a global Scientific Affairs Group to inform development decisions and trial design.
Management and execution of multi‑site Phase I/II oncology trials including site initiation, recruitment and regional coordination.
Preparation and management of regulatory filings and engagement to secure agency clearances and designation statuses that support accelerated development.
End‑to‑end development services spanning candidate validation, clinical trial design and execution, regulatory strategy, and data dissemination for oncology assets.
Independent expert appraisal of assets and indications via a global Scientific Affairs Group to inform development decisions and trial design.
Management and execution of multi‑site Phase I/II oncology trials including site initiation, recruitment and regional coordination.
Preparation and management of regulatory filings and engagement to secure agency clearances and designation statuses that support accelerated development.
Expertise Areas
- Early‑phase oncology clinical development
- Clinical trial design and operations
- Regulatory submissions and designation management
- Translational oncology and target‑driven R&D
Key Technologies
- Selective kinase inhibitors (small molecules)
- Immuno‑oncology agents (next‑generation checkpoint approaches)
- Peptide‑drug conjugates
- Nanoparticle chemotherapy formulations
News & Updates
Ellipses Pharma announced it will present clinical updates at leading U.S. breast and blood cancer conferences, highlighting progress in its oncology pipeline.
Ellipses received FDA clearance for IND application to initiate clinical trials of EP0042 in patients with acute myeloid leukemia.
The FDA granted Orphan Drug Designation to EP0031, a next-generation RET inhibitor, for the treatment of RET-altered tumors.
Ellipses has increased its portfolio to seven high-quality cancer treatment assets, with several in clinical trials and others at late preclinical stage.
Ellipses Pharma was featured in SCRIP magazine, highlighting its innovative approach to cancer drug development.
Ellipses presented clinical data and trial designs at major oncology conferences, including ASCO and SABCS.
Ellipses Pharma announced it will present clinical updates at leading U.S. breast and blood cancer conferences, highlighting progress in its oncology pipeline.
Ellipses received FDA clearance for IND application to initiate clinical trials of EP0042 in patients with acute myeloid leukemia.
The FDA granted Orphan Drug Designation to EP0031, a next-generation RET inhibitor, for the treatment of RET-altered tumors.
Ellipses has increased its portfolio to seven high-quality cancer treatment assets, with several in clinical trials and others at late preclinical stage.
Ellipses Pharma was featured in SCRIP magazine, highlighting its innovative approach to cancer drug development.
Ellipses presented clinical data and trial designs at major oncology conferences, including ASCO and SABCS.